Data Inspections in China: Increased Supervision and Compliance
Data protection inspections have become more frequent for companies with operations in China. Many companies are struggling for guidance on how to comply.
Joint Controllers: Constraint or Opportunity?
On the surface, the similarities between Facebook and Jehovah’s Witnesses are not obvious. The European Court of Justice (ECJ) has, however found one: they are both “joint controllers” of processing activities on personal data.
Pathways to Approval: Recent Developments in EU Pharma and Medical Device Regulation
The contrast between the United States and European Union is no more apparent than when we consider the approach to centralized oversight of pharma and medical device regulation.
How “Dieselgate” Expanded Into An Antitrust Investigation, and What This Means For You
Lisa M. Richman
Paul M. Thompson
The European Commission’s Dieselgate investigation shows that one problem can easily become another. To prepare for shifts in focus, companies must know when to disclose wrongdoing or seek leniency.
Cost v Care in the UK NHS
A recent judgement raises significant questions about the regulation of medicines and the role of national bodies, and fuels the debate on budget constraints being taken into account when offering treatment.
Tracking Trends in Global Collaboration and Licensing Agreements
For decades, partnering was the lifeblood of large pharma and small biotech alike. Today, small biotechs increasingly have the upper hand as technology enables more competitive products and rich capital markets decrease the deal imperative.
Risky Business: Due Diligence for Early-Stage Life Sciences Companies
The past decade has seen dramatic change within the life sciences industry, as technology develops in leaps and bounds.
Business as Unusual: Drug Companies Prepare for a Post-Brexit Health Care System
The status of the United Kingdom post-Brexit and how the life sciences industry might be affected is still up for debate.